M
12.10
2.09 (20.88%)
| 前收盘价格 | 10.01 |
| 收盘价格 | 10.08 |
| 成交量 | 224,897 |
| 平均成交量 (3个月) | 220,183 |
| 市值 | 529,946,144 |
| 市盈率 (P/E TTM) | 172.86 |
| 价格/销量 (P/S) | 2.62 |
| 股市价格/股市净资产 (P/B) | 1.50 |
| 52周波幅 | |
| 利润日期 | 14 May 2025 |
| 营业毛利率 | 31.01% |
| 营业利益率 (TTM) | 29.97% |
| 稀释每股收益 (EPS TTM) | 0.070 |
| 总债务/股东权益 (D/E MRQ) | 8.84% |
| 流动比率 (MRQ) | 16.10 |
| 营业现金流 (OCF TTM) | 69.88 M |
| 杠杆自由现金流 (LFCF TTM) | 52.09 M |
| 资产报酬率 (ROA TTM) | 23.07% |
| 股东权益报酬率 (ROE TTM) | 34.38% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Maze Therapeutics, Inc. | 看跌 | - |
AIStockmoo 评分
0.8
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.75 |
|
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 5.91% |
| 机构持股比例 | 92.16% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Trv Gp Iv, Llc | 31 Mar 2025 | 6,073,958 |
| Arch Venture Management, Llc | 31 Mar 2025 | 4,120,053 |
| Matrix Capital Management Company, Lp | 31 Mar 2025 | 2,486,184 |
| Foresite Capital Management Iv, Llc | 31 Mar 2025 | 2,111,919 |
| Ah Capital Management, L.L.C. | 31 Mar 2025 | 1,702,225 |
| General Catalyst Group Management, Llc | 31 Mar 2025 | 1,035,910 |
| Trv Gp V, Llc | 31 Mar 2025 | 950,800 |
| Logos Global Management Lp | 31 Mar 2025 | 936,914 |
| 52周波幅 | ||
| 中 | 19.00 (57.03%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Guggenheim | 02 Apr 2025 | 19.00 (57.02%) | 购买 | 10.37 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合